Darren W Davis
Overview
Explore the profile of Darren W Davis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
751
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Berger A, Davis D, Tellez C, Prieto V, Gershenwald J, Johnson M, et al.
Cancer Res
. 2005 Dec;
65(23):11185-92.
PMID: 16322269
The activator protein-2alpha (AP-2) transcription factor plays a key role in regulating expression of genes involved in tumor growth and metastasis of human melanoma. We sought to assess the prognostic...
12.
Mohamedali K, Kedar D, Sweeney P, Kamat A, Davis D, Eve B, et al.
Neoplasia
. 2005 Oct;
7(10):912-20.
PMID: 16242074
Vascular endothelial growth factor (VEGF) and its receptors (FLT-1 and KDR) are overexpressed by human bladder cancer cells and tumor endothelial cells, respectively. Strategies that target VEGF receptors hold promise...
13.
Davis D, Takamori R, Raut C, Xiong H, Herbst R, Stadler W, et al.
Clin Cancer Res
. 2005 Feb;
11(2 Pt 1):678-89.
PMID: 15701856
Purpose: To determine the effects of small molecule inhibitors of vascular endothelial growth factor receptor (VEGFR)-2 (SU5416 and SU6668) on receptor phosphorylation in tumor xenografts and in paired tumor biopsies...
14.
Raut C, Nawrocki S, Lashinger L, Davis D, Khanbolooki S, Xiong H, et al.
Cancer Biol Ther
. 2004 Oct;
3(12):1217-24.
PMID: 15477758
Previous studies suggest that antagonists of cyclooxygenases 1 and 2 (COX-1, -2) inhibit angiogenesis in tumor xenografts, but the molecular mechanisms involved remain unclear. Here we characterized the effects of...
15.
Heymach J, Desai J, Manola J, Davis D, McConkey D, Harmon D, et al.
Clin Cancer Res
. 2004 Sep;
10(17):5732-40.
PMID: 15355900
Purpose: SU5416 (semaxanib) is a small molecule inhibitor of the vascular endothelial growth factor (VEGF) receptor-2 and KIT receptor tyrosine kinases. This Phase II study was conducted to investigate the...
16.
Davis D, Inoue K, Dinney C, Hicklin D, Abbruzzese J, McConkey D
Cancer Res
. 2004 Jul;
64(13):4601-10.
PMID: 15231672
Vascular endothelial growth factor (VEGF) is a key angiogenic factor in a variety of solid tumors, making it one of the most attractive therapeutic targets. VEGF promotes the proliferation, survival,...
17.
Raut C, Takamori R, Davis D, Sweeney-Gotsch B, OReilly M, McConkey D
Cancer Biol Ther
. 2004 Jun;
3(7):679-87.
PMID: 15197351
Purpose: Recombinant human endostatin (rhES) is an antiangiogenic agent derived from collagen XVIII which inhibits tumor growth in subcutaneous models of various human malignancies. However, its effectiveness in an orthotopic...
18.
Kamat A, Karashima T, Davis D, Lashinger L, Bar-Eli M, Millikan R, et al.
Mol Cancer Ther
. 2004 Mar;
3(3):279-90.
PMID: 15026548
Bortezomib (PS-341, Velcade) is a dipeptidyl boronic acid inhibitor of the 20S proteasome that was developed as a therapeutic agent for cancer. Here, we investigated the effects of bortezomib on...
19.
Davis D, Shen Y, Mullani N, Wen S, Herbst R, OReilly M, et al.
Clin Cancer Res
. 2004 Jan;
10(1 Pt 1):33-42.
PMID: 14734449
Purpose: In a recent study, we presented preliminary evidence for biological activity in a Phase I dose-finding study (15-600 mg/m(2)) of recombinant human endostatin in patients with refractory solid tumors....
20.
Davis D, McConkey D, Zhang W, Herbst R
Biotechniques
. 2003 May;
34(5):1048-50, 1052, 1054 passim.
PMID: 12765031
No abstract available.